Information  X 
Enter a valid email address

EPIC/TIDM matching '0N4A'

Date
Time Source
Company
Announcement
19 Nov 2019 12:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus
18 Nov 2019 6:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia invites to investor meetings in connection to the rights issue
11 Nov 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia resolves on a rights issue of approximately SEK 399 million
06 Nov 2019 3:35 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019
14 Oct 2019 7:48 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Notice of extraordinary general meeting in Oasmia Pharmaceutical AB
  7:46 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million
26 Sep 2019 6:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019
  6:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019
18 Sep 2019 7:45 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte
  7:20 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia presents Q1 report through audiocast on September 26
15 Sep 2019 8:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019
05 Sep 2019 2:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia publishes its annual report and adjusts accounts due to write-downs - auditors do not recommend former board to be granted discharge from liability
04 Sep 2019 8:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia completes its management team
28 Aug 2019 10:15 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Notice of Annual General Meeting in Oasmia Pharmaceutical AB
27 Aug 2019 2:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia updates regarding MGC disputes
23 Aug 2019 9:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia ADSs delisted from NASDAQ in the US
20 Aug 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Nomination committee in Oasmia for the 2019 AGM
15 Aug 2019 1:30 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar
02 Aug 2019 4:40 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs
31 Jul 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) New number of shares and votes in Oasmia Pharmaceutical AB (publ)
09 Jul 2019 11:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia discontinues cooperation with former executive chairman
05 Jul 2019 12:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia
04 Jul 2019 8:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia appoints Business Advisory Board
02 Jul 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia appoints Scientific Advisory Board
  7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia appoints new CMO
28 Jun 2019 6:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia announces change of CEO
  6:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner
  6:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019
26 Jun 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia presents full-year report and status in the Board's review through audiocast on June 28
25 Jun 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Two studies finalized in Oasmia Pharmaceutical’s Docecal programme
15 May 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia postpones the release of the Q4 and year-end report to 28 June
10 Apr 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia expands the Management Team
03 Apr 2019 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Short report of the status of the review in Oasmia
28 Mar 2019 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.
26 Mar 2019 12:00 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Notification from Oasmia Pharmaceutical AB
  7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) CFO of Oasmia, Anders Blom has resigned
25 Mar 2019 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information
21 Mar 2019 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) New Board starts reviewing the situation in Oasmia
19 Mar 2019 9:30 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019
18 Mar 2019 3:10 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia announces a prospectus regarding admission to trading of new shares
06 Mar 2019 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical Strengthens its Management Team and Organization
04 Mar 2019 7:49 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia has completed a directed share issue of approximately 165 MSEK
01 Mar 2019 7:15 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB (publ)
05 Feb 2019 9:50 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) - UPDATED VERSION
  9:32 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)
31 Jan 2019 9:05 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
22 Jan 2019 9:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019
21 Jan 2019 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled
15 Jan 2019 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information
17 Dec 2018 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting
14 Dec 2018 4:40 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)
30 Nov 2018 9:30 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
  7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018
29 Nov 2018 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®
28 Nov 2018 9:30 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company’s warrants 2018/2019
22 Nov 2018 10:58 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
20 Nov 2018 7:30 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
01 Nov 2018 12:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million
31 Oct 2018 10:56 pm GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
03 Oct 2018 7:00 am GNW Factsheet Oasmia Pharmaceutical AB (0N4A) Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t